Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)

Joseph Carmicheal; Asish Patel; Vipin Dalal; Pranita Atri; Amaninder S Dhaliwal; Uwe A Wittel; Mokenge P Malafa; Geoffrey Talmon; Benjamin J Swanson; Shailender Singh; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra

doi:10.1016/j.bbcan.2019.188318

Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)

Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188318. doi: 10.1016/j.bbcan.2019.188318. Epub 2019 Oct 30.

Authors

Affiliations

¹ Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
² Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
³ Department of Internal Medicine, Division of Gastroenterology-Hepatology, University of Nebraska Medical Center, Omaha, NE, USA.
⁴ Department of General- and Visceral Surgery, University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany.
⁵ Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
⁶ Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
⁷ Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
⁸ Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: skaur@unmc.edu.
⁹ Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: sbatra@unmc.edu.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.

Keywords: Biomarker; Early detection; IPMN; Pancreatic cancer; Pancreatic cystic lesions; Pancreatic ductal adenocarcinoma; Radiomics.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Biomarkers, Tumor / analysis
Carcinoma, Pancreatic Ductal / diagnosis*
Disease Progression
Early Detection of Cancer / methods*
Pancreas / pathology
Pancreatic Cyst / diagnosis*
Pancreatic Neoplasms / diagnosis*
Precancerous Conditions / diagnosis*
Risk Factors
Survival Analysis

Substances

Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding